Overview
The objective of this study is to monitor the usage of Lorviqua in real practice within label, including the adverse events associated with Lorviqua
Eligibility
Inclusion Criteria:
Patients must meet all of the following inclusion criteria to be eligible for inclusion in
the study:
1. Use in the treatment of adult patients with anaplastic lymphoma kinase (ALK)-positive
metastatic non-small cell lung cancer (NSCLC)
2. Evidence of a personally signed and dated informed consent document indicating that
the patient (or a legally acceptable representative) has been informed of all
pertinent aspects of the study.
Exclusion Criteria:
Patients meeting any of the following criteria will not be included in the study:
1. Patients to whom Lorviqua® is contraindicated as per the local labeling. A.
Hypersensitivity to Lorviqua® or to any of the excipients of this product B. Lorviqua®
is contraindicated in patients taking concomitant use of strong CYP3A4/5 inducers C.
This medicinal product contains lactose as an excipient. Patients with rare hereditary
problems of galactose intolerance, total lactase deficiency, or glucose galactose
malabsorption should not take this medicinal product.
2. Any patients (or a legally acceptable representative) who does not agree that Pfizer
and companies working with Pfizer use his/her information